Christie to mass produce its CounterAct far UVC light products


As we prepare for a post-pandemic world where reducing pathogens and viral spread is essential, a global visual technology company Christie announced the serial production of its Christie CounterAct commercial UV disinfection product line with patented Care222 far UVC light technology. CounterAct luminaires are designed for use in busy indoor spaces, cinemas, theme parks, museums and sports complexes, retail stores, restaurants, as well as transit centers at airports, train stations and stations. Metro.

Developed by Christie and using parent company Ushio Inc.Care222nm UV lamp technology which is licensed by Columbia University, the CounterAct range of mounted luminaires is designed for high ceiling applications, which are as easy to install as commercial lighting fixtures.

The first UV disinfection technology developed for use around people, Christie CounterAct uses proprietary filtered far UVC light to remove 99% of pathogens from surfaces in indoor spaces, including the coronavirus SARS-CoV-2 which causes COVID- 19, influenza, bacteria, and other antibiotic-resistant superbugs by damaging the pathogen’s DNA or RNA, rendering them unable to reproduce and infect humans.

“With our CounterAct devices, as an added layer of defense, bringing customers back to the places they love to share and creating memorable experiences has never been safer,” said Brian Claypool, Executive Vice President, Cinema , Christie. “Many businesses and industries around the world rely on the ability to bring their customers together in person, and they will need all the tools available to help them do so safely. “

To date, Christie CounterAct models have demonstrated compliance with UL, CE, and UKCA standards through third-party testing facilities for electrical safety, electromagnetic compatibility (EMC), compliance with the Radio Equipment Directive, and most importantly, photobiological safety.

Photobiological compliance is a safety assessment to confirm that the level of UV exposure for occupants meets accepted industry guidelines – a critical part of third-party testing.

Christie CounterAct commercial UV disinfection devices with patented Care222 technology. Photo courtesy of Christie.
Advances in technology have made UV disinfection safer and more efficient

UV light has long been proven to neutralize pathogens effectively, but the 254nm wavelength used in other disinfection products on the market is a danger to human health as it can penetrate and damage the eyes. and human skin, making it hazardous for human exposure.

Award-winning CounterAct luminaires contain Ushio’s patented Care222 lamps which emit far UVC light of 222nm – which has been shown in a 2020 study from Kobe University safe to use with bystanders, making it an ideal spot on the UV spectrum that is effective against pathogens in occupied spaces. In addition, Care222 is the world’s first far UVC technology with a proprietary optical filter that prevents the emission of potentially harmful UVC wavelengths (> 230nm).

“The main advantage is that the unique distant UVC light of our Christie CounterAct UVC disinfection devices can be used automatically and continuously in the presence of people. The technology is reducing pathogens from the environments where people congregate, ”Claypool said. “By harnessing these advantages in a user-friendly product that can be quickly deployed, we hope to give a much needed boost to our partners in many industries. “

Christie CounterAct products featuring patented Care222 technology are not medical devices and are not intended for use as or for medical devices.

Leave A Reply

Your email address will not be published.